2020
DOI: 10.1007/978-1-0716-0759-6_14
|View full text |Cite
|
Sign up to set email alerts
|

Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(4 citation statements)
references
References 120 publications
0
4
0
Order By: Relevance
“…Tumor-bearing humanized mice injected with CAR pT cells resulted in a drastic reduction in their survivability, when compared to that after CAR pNK treatment. It is conceivable that one of the side effects of T cell–mediated therapy is the induction of CRS, which is featured by a massive release of inflammatory cytokines, including IFN-γ, tumor necrosis factor–α, IL-6, and IL-10 ( 11 , 59 ). Consistently, we found that plasma concentrations of IFN-γ, IL-6, and IL-10 were significantly up-regulated in tumor-bearing humanized mice after CAR pT treatment but not in the CAR pNK cell–treated mice.…”
Section: Discussionmentioning
confidence: 99%
“…Tumor-bearing humanized mice injected with CAR pT cells resulted in a drastic reduction in their survivability, when compared to that after CAR pNK treatment. It is conceivable that one of the side effects of T cell–mediated therapy is the induction of CRS, which is featured by a massive release of inflammatory cytokines, including IFN-γ, tumor necrosis factor–α, IL-6, and IL-10 ( 11 , 59 ). Consistently, we found that plasma concentrations of IFN-γ, IL-6, and IL-10 were significantly up-regulated in tumor-bearing humanized mice after CAR pT treatment but not in the CAR pNK cell–treated mice.…”
Section: Discussionmentioning
confidence: 99%
“…Chimeric antigen receptors (CARs), so named because they artificially fuse antigen-binding domains to specific cell-activating domains [ 18 ], have brought the gene therapy field some of its first clinical and commercial achievements (e.g., Kymriah ® , Yescarta ® ). Although CAR T cell therapy has been successful, particularly for hematological malignancies [ 19 ], improvements are still needed. The therapy can be immunogenic and the protocol for developing and delivering the T cells is expensive, complicated, and takes several weeks.…”
Section: Using Minimized Dna Vectors For Cancer Therapymentioning
confidence: 99%
“…The resultant CD44-CAR T cells resembled normal T cells in cytokine profile and phenotype, specifically lysed CD44 + cell lines and not CD44- cell lines, and suppressed tumor growth in vivo compared to controls [ 21 ]. This result was important as it demonstrated the efficacy of minicircle-generated CAR T cells against a solid tumor, which is more challenging to treat than the diffuse lymphomas treated previously [ 19 ].…”
Section: Using Minimized Dna Vectors For Cancer Therapymentioning
confidence: 99%
“…In most cases, CD19 CAR-T cells deplete normal CD19+ B cells, resulting in hypogammaglobulinemia in patients. Despite multiple immune impairments in patients receiving CD19 CAR-T cell immunotherapy, the infectious complications of this therapy have not been systematically studied [10,11]. In this study, the infection epidemiology of 40 leukemia patients in our hospital after CD19 CAR-T cell immunotherapy was collected to preliminarily explore the factors that lead to the high risk of infection in patients, and provide a basis for future clinical treatment.…”
Section: Introductionmentioning
confidence: 99%